Our Recommendation

Showing posts with label Major. Show all posts
Showing posts with label Major. Show all posts

Wednesday, December 15, 2010

Major challenge for mediation in Medical Malpractice: doctor participation (WSJ)

A study of mediation in cases of medical malpractice finds this approach possible benefits, including lower costs of litigation and a reduction in medical errors. A key ingredient missing, however, is the doctors themselves.

The study, published in the journal of Health Politics, Policy and Law, looked in 31 cases mediation in non-profit hospitals in New York. As defined by the study, mediation is a "conflict voluntary, confidential resolution process in which a third party neutral party, the Ombudsman (or co-mediators), helps the parties to negotiate a mutually acceptable solution."

One of two principal investigators of the co-mediated in almost all cases, and conducted interviews with participants subsequently law students study.

In these cases, 16 were settled at mediation, 5 settled subsequently and 10 have not been settled. While defence counsel are least likely to agree to mediation that counsel for the plaintiff lawyers who engages reported satisfaction with the process, such as "the applicants, the representatives of the hospital and the insurers," the study concluded.

The authors write that in no case have physicians participate in mediation. Lacking some of the possibilities - first "repair the relationship between human beings," it is the doctor-patient (or family of the patient), Carol Liebman, co-author of the study, a Professor of law at the Faculty of Columbia law school mediation clinic Director tells health Blog. " It also misses the opportunity to gather information from patients, families and physicians to fill the empty spaces of what is really past, and if there is an error, how to prevent it from happening once again, she says. Used in the study mediation approach holds that any important information to someone at the table, not only what is legally relevant can be discussed. (The information disclosed during mediation are confidential).

When you do not have the participation of "the person who is involved in these decisions, the day and the day, you get valuable information", Liebman said. "Use of a lawyer is to defend the case not reshape politics." Mediation, says, offers the possibility to improve patient safety in a dispute in a way impossible.

Counsel cited as a pattern of absences physicians complete work schedules, the study found. Liebman believes that many things are underway. "Doctors and nurses care much about their work and they feel horrible when something go wrong", she says. "They want to talk about their patients, but it is not easy to do." They are also probably discouraged from attending by the directors of the hospital and the lawyers who think in advance so that if the case goes to trial.

Doctor health blog readers, never would you consider mediation if involved in a malpractice lawsuit medical?

Image: courtesy

Thursday, December 9, 2010

Major US breast cancer trial drug disappoints (Yahoo!)

A major trial to see if a common bone-building drug could help prevent the recurrence of breast cancer found do not receive the majority of patients, doctors, said Thursday.

Five years, called the trial study AZURE, followed 3,360 women with advanced breast cancer who had undergone surgery.

Some take the drug Zometa, also called the zoledronic acid, in addition to standard therapy randomly osteoporosis study. Zometa is made by the Switzerland pharmaceutical giant Novartis.

The hope was prevents cancer resurfacing, as it often does in the bones of the survivor.

But the American Association for cancer research has found that the drug have no impact on "" for the group as a whole"disease-free survival.

"Overall population, we did not see a difference", said Robert Coleman, Professor of medical oncology at the University of Sheffield, England, who presented the results of a Conference in San Antonio, Texas.

He added, however, there was a slight difference between age groups, with elderly patients a little more exiting on the drug.

30% Of the group who were postmenopausal at least five years, 1,101 overall, has seen an improvement of 29 per cent overall survival, which was "not likely to be a chance to find" said Coleman.

"We clearly want investigate later in this population."

He added, however, that "young patients receive no benefit." If they do worse. »

Zoledronic acid is a bisphosphonate that works by reducing the amount of calcium released by bones in the blood.

It is used to treat blood calcium levels that may coincide with cancer and to prevent fractures in patients with cancer.